Cross-Sector entity
Axon Enterprise is the most frequent co-covered peer, appearing in 3 of the 3 tracked stories. Coverage clusters in earnings, which accounts for 1 of those 3, with the remainder spread across 2 other categories. Each carries 3 original sources on average.
3 verified stories tracked
Last mentioned: Feb 23, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Axon Enterprise is the most frequent co-covered peer, appearing in 3 of the 3 tracked stories. Coverage clusters in earnings, which accounts for 1 of those 3, with the remainder spread across 2 other categories. Each carries 3 original sources on average. We currently track 3 Cross-Sector stories that mention Corcept Therapeutics, all published on February 23, 2026.
Computed from the 3 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Corcept Therapeutics. Shared-story counts are live from our verified record — not editorial picks.
Axon Enterprise is set to report Q4 2025 results, with investors focused on the adoption of AI-driven tools like Draft One and the continued rollout of TASER 10. Meanwhile, specialty pharma players Corcept and Supernus prepare to disclose their own year-end performance amid shifting regulatory and competitive landscapes.
Supernus Pharmaceuticals and Corcept Therapeutics are preparing to report Q4 2025 results, with investors focusing on CNS product growth and cortisol-modulating pipeline progress. These reports will provide critical data on market penetration for key therapies like Qelbree and Korlym amidst a shifting regulatory landscape.
Investors are bracing for Q4 2025 results from Axon Enterprise, Supernus Pharmaceuticals, and Corcept Therapeutics, with Axon looking to maintain its perfect revenue beat streak. While Axon dominates the public safety tech space, the pharmaceutical players face varying expectations regarding clinical pipelines and market penetration for core therapies.
Source: Seeking Alpha · Seeking Alpha
